SOUTH CAROLINA BOARD OF HEALTH AND ENVIRONMENTAL CONTROL

Placement of Serdexmethylphenidate in Schedule IV for Controlled Substances

WHEREAS, pursuant to S.C. Code Section 44-53-160(C), the S.C. Board of Health and Environmental Control (Board) shall designate a substance as a controlled substance by scheduling it in accordance with an order effecting federal scheduling as a controlled substance;

WHEREAS, the U.S. Department of Justice, Drug Enforcement Administration (“DEA”), issued an interim final rule placing serdexmethylphenidate and its salts in schedule IV of the federal Controlled Substance Act, effective May 7, 2021. F.R. Volume 86, Number 87, pp. 24487-24492;

WHEREAS, serdexmethylphenidate is a new molecular entity without CNS activity. However, according to HHS, because serdexmethylphenidate chloride is metabolized in the large intestine to dexamethylphenidate (“d-MPH”), a schedule II drug and a CNS stimulant, SDX is a prodrug of d-MPH. The U.S. Food and Drug Administration have recently approved the use of serdexmethylphenidate for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients six years of age or older;

WHEREAS, serdexmethylphenidate has a low potential for abuse relative to the drugs or other substances in schedule III, a currently accepted medical use in the United States, and may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III; therefore, serdexmethylphenidate should be placed in schedule IV of the federal Controlled Substances Act effective May 7, 2021; and

THEREFORE, the Board of Health and Environmental Control adopts the federal scheduling of serdexmethylphenidate and amends Section 44-53-250 of the South Carolina Code of Laws by adding and designating into Schedule IV of the South Carolina Controlled Substances Act: serdexmethylphenidate.

Mark Elam, Chairman
S.C. Board of Health and Environmental Control

May 13, 2021
Columbia, South Carolina